MARLTON, N.J., July 19, 2021 — Impulse Dynamics (USA) Inc., a company dedicated to improving the lives of people with heart failure (HF), today announced the appointment of Jason Spees to the position of President, Chief Commercial Officer. Spees, who will be based in the company’s headquarters office in Marlton, N.J., brings nearly 20 years of commercial success in the medical device industry, most recently at Biotronik, where he implemented a new commercial strategy driving strong market share growth across all divisions. Prior to Biotronik, Jason was Executive Vice President and Chief Commercial Officer for digital health and diagnostics company Preventice Solutions, and also served in commercial roles at Boston Scientific in cardiac rhythm management, interventional cardiology, electrophysiology, and diagnostics. Jason was also a captain in the United States Air Force and received a Bachelor of Science degree in Operations Research and Engineering from the United States Air Force Academy with academic distinction, and holds a Master of Arts in Public Management – Finance from the University of Maryland.
“We are very pleased to be welcoming Jason to Impulse Dynamics,” said Dr. Simos Kedikoglou, CEO of Impulse Dynamics. “Given the strong demand for CCM® therapy in the U.S. and abroad, his leadership and experience will be critical assets for Impulse Dynamics. Capitalizing on our global regulatory approvals and our supportive reimbursement, Jason will further build our commercial team and processes to drive strong business execution and help Team Impulse Dynamics reach the numerous heart failure patients that can benefit from CCM therapy in the U.S. and worldwide.”
“Heart failure is a devastating disease, and it is exciting to be a part of getting the revolutionary Optimizer Smart technology to the heart failure patients that can benefit from the therapy, while also driving value for shareholders,” said Spees. “Impulse Dynamics continues to gain momentum, and I am eager to help bring this breakthrough device to more patients in need of this therapeutic alternative.”
CCM therapy is the first approach of its kind designed to improve contraction of the heart, potentially allowing more oxygen-rich blood to reach the body. This breakthrough technology can enhance the quality of life for patients who are no longer adequately responding to medications to manage their symptoms.
About Impulse Dynamics
Impulse Dynamics is dedicated to helping healthcare providers enhance the lives of people with heart failure by transforming how the condition is treated. The company is focused on delivering its proprietary CCM therapy, which is delivered by the company’s Optimizer device, the CE-marked, and FDA-approved treatment verified to improve the quality of life for heart failure patients. CCM therapy is a safe, effective, and minimally invasive treatment option for many heart failure patients who otherwise have few effective options available to them.1 To learn more, visit www.ImpulseDynamics.com, or follow the company on LinkedIn, Twitter, and Facebook.
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy, and the absence of risks associated therewith; the ability for CCM therapy and our products to fill a significant unmet medical need for patients with heart failure; and the short-term and long-term benefits of the Optimizer and CCM therapy in patients with heart failure, as well as to the physicians treating those patients. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.
Impulse Dynamics (USA), Inc.
50 Lake Center Executive Park, 401 Route 73 N, ‐ Building 50 Suite 100
Marlton, NJ 08053
Phone: (856) 642‐9933
Global Vice President, Marketing